RxDoctor Payments Data

Mariano Salinas, MD

Family Medicine · McAllen, TXNPI 1134129950

Payments from drug & device makers

$2,438in general payments, 2019–2025

Across 107 payments — averaging $22.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$822
  • AstraZeneca$784
  • Pfizer$130
  • Boehringer Ingelheim$121
  • Astellas Pharma US Inc$102
  • Novo Nordisk$95
  • plus $384 from 12 others

What the payments were for

  • Food & beverage$2,33996%
  • Education$994%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,438 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$15,045
Medicare patients
31
Services billed
320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$65,866
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$46,307
FarxigaDapagliflozin Propanediol18$25,292
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr33$20,603
JanumetSitagliptin Phos/Metformin Hcl15$20,241
EntrestoSacubitril/Valsartan14$18,809
JardianceEmpagliflozin13$15,152
LinzessLinaclotide13$11,848
JanuviaSitagliptin Phosphate12$10,071
Celecoxib106$7,568
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide84$3,371
Levemir FlexpenInsulin Detemir11$2,833
PaxlovidNirmatrelvir/Ritonavir11$1,359
Atorvastatin Calcium205$1,349
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide70$1,296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$95$66,90987 claims
Novo NordiskOzempic$95$65,86649 claims
AstraZenecaFarxiga$784$25,29218 claims
NovartisEntresto$20$18,80914 claims
Boehringer IngelheimJardiance$121$15,15213 claims
PfizerPaxlovid$130$1,35911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →